PUBLISHER: GlobalData | PRODUCT CODE: 1725994
PUBLISHER: GlobalData | PRODUCT CODE: 1725994
Currently, there are seven marketed cell and gene therapies (CGTs) for various dermatology disorders. This includes one gene therapy and six cell therapies. Biosolution's KeraHeal, indicated for the treatment of burns in pediatric and adult patients, was the first autologous keratinocyte cell-based therapy to receive approval in the dermatology market in 2006, by the Ministry of Food and Drug Safety (MFDS) in South Korea. Over the past decade, there has been an increase in the number of approved CGTs for dermatology disorders. However, the market has also faced several discontinuations of CGT development programs, especially in the EU, primarily driven by the high cost of development, lack of funding, and safety concerns.
Both marketed therapies are prescribed when a patient has shown an inadequate response to at least one conventional or biologic therapy.